Hormone therapy in postmenopausal osteoporosis: 2008

Ascott-Evans, Brynne; Sonnendecker, E. W. W.; Villiers, T de

doi:10.1080/22201009.2008.10872165

Cited by 2 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 The synthetic steroid tibolone has weak estrogenic, progestogenic and androgenic properties and prevent postmenopausal bone loss. 44 In LIFT clinical study was found that tibolone signifi cantly reduces vertebral and non-vertebral fractures. 44 Effects of testosterone is effected by the activation of androgen receptors, and by conversion into estradiol.…”

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 97%

“…44 In LIFT clinical study was found that tibolone signifi cantly reduces vertebral and non-vertebral fractures. 44 Effects of testosterone is effected by the activation of androgen receptors, and by conversion into estradiol. In males with hypogonadism treated with depo-testosterone 200 mg intramuscular injection bone resorption is reduced.…”

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 97%

“…The combination of these two groups of agents has additive effects on the reduction of bone resorption markers and BMD. 43,44 Estradiol is an agonist of nuclear steroid estrogen (ER) receptors: ERα and ERβ and intracellular membrane non-nuclear estrogen receptor GPER Folia Medica 2015; 57(3&4): 181-190 © 2015 Medical University, Plovdiv and inhibits bone resorption. 42 In osteoporosis Estradiol could be administered also transdermally.…”

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 99%

“…43 Hormone replacement therapy is allowed up to 3 years and at the lowest therapeutic dose (mainly as skin patches) when the expression of heavy menopausal symptoms and osteoporosis is combined. 43,44 Hormonal therapy reduces the risk of osteoporotic fractures, improves bone mineral density (BMD), suppresses biochemical markers of bone resorption, and reduces the loss of bone mass. 1,3,4,42 The mechanism of action of estrogens differs from that of bisphosphonates.…”

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 99%

See 3 more Smart Citations

Osteoporosis: Therapeutic Options

Ivanova¹,

Vasileva²,

Ivanova³

et al. 2016

Folia Medica

View full text Add to dashboard Cite

The definition of osteoporosis was originally formulated at a conference of the World Health Organization (WHO) in 1993 as 'a systemic skeletal disease characterized by decreased bone mass and altered micro-architecture of bone tissue, leading to enhanced bone fragility and risk of fractures'. Osteoporosis is characterized by low bone mineral density (BMD) and loss of the structural and bio-mechanical properties that are required to maintain bone homeostasis. This review aims to address the currently available options in prevention and treatment of osteoporosis. Management of osteoporosis includes non-pharmacological treatment - diet rich of calcium and vitamin D, healthy lifestyle, proper exercise plan, and pharmacological therapy. Combination of non-pharmacological and pharmacological treatment options have to be considered for prevention of osteoporosis and minimization of the risk of fractures. Given the heterogeneity of osteoporosis syndrome and lack of significant number of comparative studies, the choice of a pharmacological agents should be individualized.

show abstract

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 97%

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 97%

Section: Hormone Replacement Therapy (Hrt)mentioning

confidence: 99%